Recent insights into the role of prostanoids in atherosclerotic vascular disease

Current Vascular Pharmacology

Volumn 4, Issue 4, 2006, Pages 395-408

  Reiss, Allison B ^a   Edelman, Sari D ^a  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

Atherosclerosis; Eicosanoid; Prostaglandin; Vascular disease

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; BERAPROST; CILOSTAZOL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ECRAPROST; ENDOTHELIN 1; HIRUDIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILOPROST; IRBESARTAN; LICOFELONE; LOSARTAN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PENTOXIFYLLINE; PICOTAMIDE; PLACEBO; PROPRANOLOL; PROSTACYCLIN; PROSTAGLANDIN D2; PROSTAGLANDIN E1; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN H2; PROSTANOID; RIDOGREL; SIMVASTATIN; THROMBOXANE; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; THROMBOXANE SYNTHASE; ICOSANOID; PROSTAGLANDIN;

ARTERY DISEASE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; CLAUDICATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DOSE RESPONSE; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HUMAN; META ANALYSIS; MORBIDITY; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULAR DISEASE; ANIMAL; ATHEROSCLEROSIS; BIOSYNTHESIS; CARDIOVASCULAR DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

ANIMALS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; EICOSANOIDS; ENDOTHELIUM, VASCULAR; HUMANS; PROSTAGLANDINS; SIGNAL TRANSDUCTION; VASCULAR DISEASES;

EID: 34249047637     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016106778521652     Document Type: Review

References (113)

1. Harris: Kelley's Textbook of Rheumatology, 7th ed., Copyright © 2005 Saunders, An Imprint of Elsevier.
2. Reiter M, Bucek RA, Stumpflen A, Minar E. Prostanoids for intermittent claudication. Cochrane Database Syst Rev 2004; (1): CD000986
3. th Edition. Unit I, Chapter 2, pp. 47-49: Chemical Mediators of Inflammation, 2006 Elsevier.
4. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001; 294: 1871-1875.
5. Vane JR, Anggard EE, Botting RM. Regulatory function of the vascular endothelium. N Engl J Med 1990; 323: 27-36.
6. Mayes MD. Endothelin and endothelin receptor antagonists in systemic rheumatic disease. Arthritis Rheum 2003; 48(5): 1190-1199.
7. Levin ER. Endothelins. N Engl J Med 1995; 333: 356-363.
8. Thiemermann C, Lidbury PS, Thomas GR, Vane JR. Endothelin-1 releases prostacyclin and inhibits ex vivo platelet aggregation in the anesthetized rabbit. J Cardiovasc Pharmacol 1989; 13 (Suppl 5): S138-41.
9. Miura K, Yukimura T, Yamashita Y, Shimmen T, Okumura M, Yamanaka S, et al. Renal and femoral vascular responses to endothelin-1 in dogs: role of prostaglandins. J Pharmacol Exp Ther 1991; 256: 11-7.
10. Coughlin SR, Camerer E. PARticipation in inflammation. J Clin Invest 2003; 111: 25-27.
11. Coughlin SR Thrombin signalling and protease-activated receptors. Nature 2000; 407: 258-264.
12. Yang Z, Arnet U, Bauer E, von Segesser L, Siebenmann R, Turina M, Luscher TF. Thrombin-induced endothelium-dependent inhibition and direct activation of platelet-vessel wall interaction. Role of prostacyclin, nitric oxide, and thromboxane A2. Circulation 1994; 89(5): 2266-2272.
13. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263: 663-665.
14. McAdam BF, Catella-Lawson F, Mardini I, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX): the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999; 96: 272-277.
15. Adatia I, Barrow SE, Stratton PD, Miall-Allen VM, Ritter JM, Haworth, SG. Thromboxane A2 and prostacyclin biosynthesis in children and adolescents with pulmonary vascular disease. Circulation 1993; 88(5 Pt 1): 2117-2122.
16. Fabre JE, Nguyen M, Athirakul K, Coggin K, McNeish JD, Austin S, Parise LK, FitzGerald GA, Coffman TM, Koller BH. Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation. J Clin Invest 2001; 107(5): 603-610.
17. FitzGerald GA, Brash AR, Falardeau P, Oates JA. Estimated rate of prostacyclin secretion into the circulation of normal man. J Clin Invest 1981; 68: 1272-1275.
18. Reilly J, Miralles M, Wester W, Sicard G. Differential expression of prostaglandin E2 and interleukin-6 in occlusive and aneurysmal aortic disease. Surgery 1999; 126: 624-628.
19. Mihai K, Peto J, Kolthay E, Makary A, Timar S, Lusztig G. Plasma prostacyclin and thromboxane concentration in healthy children and in offspring of parents suffering from myocardial infarct. Orvosi Hetilap 1991; 132(30): 1627-1629.
20. Cipollone F, Rocca B, Patrono C. Cyclooxygenase-2 expression and inhibition in atherothrombosis. Arterioscler Thromb Vasc Biol 2004; 24: 246-255.
21. Davidge ST. Prostaglandin H synthase and vascular function. Circ Res 2001; 89(8): 650-660.
22. Schonbeck U, Sukhova GK, Graber P, Coulter S, Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 1999; 155: 1281-1291.
23. Hong BK, Kwon HM, Lee BK, Kim D, Kim IJ, Kang SM, Jang Y, Cho SH, Kim HK, Jang BC, Cho SY, Kim HS, Kim MS, Kwon HC, Lee N. Coexpression of cyclooxygenase-2 and matrix metalloproteinases in human aortic atherosclerotic lesions. Yonsei Med J 2000; 41: 82-88.
24. Davidge ST, Hubel CA, McLaughlin MK. Cyclooxygenase-dependent vasoconstrictor alters vascular function in the vitamin E-deprived rat. Circ Res 1993; 73: 79-88.
25. Mitchell JA, Evans TW. Cyclooxygenase-2 as a therapeutic target. Inflamm Res 1998; 47 (suppl II): S88-S92.
26. Maier JA, Barenghi L, Bradamante S, Pagani F. Modulators of oxidized LDL-induced hyperadhesiveness in human endothelial cells. Biochem Biophys Res Commun 1994; 204: 673-677.
27. Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1- and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102: 840-845.
28. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-1102.
29. Burleigh ME, Babaev VR, Oates JA, Harris RC, Gautman S, Riendeau D, Marnett LJ, Morrow JD, Fazio S, Linton MF. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation 2002; 105: 1816-1823.
30. Olesen M, Kwong E, Meztli A, Kontny F, Seljeflot I, Arnesen H, Lyngdorf L, Falk E. No effect of cyclooxygenase inhibition on plaque size in atherosclerosis-prone mice. Scand Cardiovasc J 2002; 36: 362-367
31. Rott D, Zhu J, Burnett MS, Zhou YF, Zalles-Ganley A, Ogunmakinwa J, Epstein SE. Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice. J Am Coll Cardiol 2003; 41: 1812-1819.
32. Reiss AB, Rahman MM, Chan ES, Montesinos MC, Awadallah NW, Cronstein BN. Adenosine A2A receptor occupancy stimulates expression of proteins involved in reverse cholesterol transport and inhibits foam cell formation in macrophages. J Leukoc Biol 2004; 76(3): 727-34.
33. Chan ES, Zhang H, Fernandez P, Cronstein BN, Pillinger MH, Ragolia L, Carsons S, Reiss AB. Cox-2-selective inhibitors interfere with cholesterol transport: a possible mechanism for atherogenic effects. Arthritis Rheum 2005; 52(9) Supplement: S354.
34. Edelman SD, Chan ES, Zhang H, Cronstein BN, Ragolia L, Palaia T, Carsons S, Reiss AB. COX-2 inhibition promotes atheromatous foam cell transformation in THP-1 human macrophages: a possible mechanism for increased cardiovascular risk. Arthritis Rheum 2005; 52(9) Supplement: S354.
35. Pillinger MH, Dinsell V, Apsel B, Tolani SN, Marjanovic N, Chan ES, Gomez P, Clancy R, Chang LF, Abramson SB. Regulation of metalloproteinases and NF-kappaB activation in rabbit synovial fibroblasts via E prostaglandins and Erk: contrasting effects of nabumetone and 6MNA. Br J Pharmacol 2004; 142(6): 973-982.
36. Pillinger MH, Rosenthal PB, Tolani SN, Apsel B, Dinsell V, Greenberg J, Chan ES, Gomez PF, Abramson, SB. Cyclooxygenase-2-derived E prostaglandins down-regulate matrix metalloproteinase-1 expression in fibroblast-like synoviocytes via inhibition of extracellular signal-regulated kinase activation. J Immunol 2003; 171(11): 6080-6089.
37. Ye S, Gale CR, Martyn CN. Variation in the matrix metalloproteinase-1 gene and risk of coronary heart disease. Eur Heart J 2003; 24(18): 1668-1671.
38. 2-dependent plaque instability. Circulation 2001; 104: 921-927.
39. Ghigo D, Treves S, Bussolino F, Libero L, Orzan F, Bazzan M, Pannocchia A, Tamponi G, Bosia A. Platelet arachidonic acid metabolism in patients with cardiovascular disorders. Biomed Biochim Acta 1988; 47: S299-302.
40. Davis B, Zou H. CD40 Ligand-dependent tyrosine nitration of prostacyclin synthase in vivo. Circulation 2005; 112(14): 2184-2192.
41. Webb NR. Secretory phospholipase A2 enzymes in atherogenesis. Curr Opin Lipidol 2005; 16(3): 341-344.
42. Murakami M, Kudo I. New phospholipase A2 isozymes with a potential role in atherosclerosis. Curr Opin Lipidol 2003; 14: 431-436.
43. Punzengruber C, Silberbauer K. Effect of angiotensin II infusion on a prostaglandin I2-metabolite and on left ventricular function. Basic Res Cardiol 1986; 81(3): 283-288.
44. Kurita A, Takase B, Uehata A, Satomura K, Sugawara H, Kondo S, Arakawa K, Shibuya T, Isojima K, Mizuno K . The role of prostacyclin during exercise in patients with chronic angina pectoris. Jpn Heart J 1988; 29(4): 401-413.
45. Wang YP, Xu H, Mizoguchi K, Tsuruhara Y, Oe M, Maeta H. Effects of prostaglandins on baroreflex during reperfusion of the ischaemic myocardium..Clin Exp Pharmacol Physiol 2000; 27(5-6): 406-11.
46. Fitscha P, Kaliman J, Sinzinger H. Platelet sensitivity to antiaggregatory prostaglandins (PGE1,D2,I2) in patients with peripheral vascular disease. Am J Hematol 1985; 19(1):13-9.
47. Mueller MR, Salat A, Stangl P, Murabito M, Pulaki S, Boehm D, Koppensteiner R, Ergun E, Mittlboeck M, Schreiner W, Losert U, Wolner E. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thrombosis Haemostasis 1997; 78(3):1003-7.
48. Gianetti J, De Caterina M, De Cristofaro T, Ungaro B, Guercio RD, De Caterina R. Intravenous prostaglandin E1 reduces soluble vascular cell adhesion molecule-1 in peripheral arterial obstructive disease. Am Heart J 2001; 142(4):733-739.
49. Matsui K, Ikeda U, Murakami Y, Yoshioka T, Shimada K. Intravenous prostaglandin E1 reduces monocyte chemoattractant protein-1 levels in peripheral arterial obstructive disease. Am Heart J 2003; 145(2): 330-333.
50. Patrono C, FitzGerald GA. Isoprostanes: Potential Markers of Oxidant Stress in Atherothrombotic Disease. Arterioscler Thromb Vasc Biol 1997; 17(11): 2309-2315.
51. Jeremy JY, Muzaffar S, Angelini GD, Shukla N. Regarding "Serum total 8-iso-prostaglandin F2alpha: a new and independent predictor of peripheral arterial disease". J Vasc Surg 2005; 41(2): 373; author reply 373-374.
52. Nowak J, Murray JJ, Oates JA, FitzGerald GA. Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes. Circulation 1987; 76: 6-14.
53. Bazzano LA, He J, Muntner P, Vupputuri S, Whelton PK. Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med 2003; 138: 891-897.
54. 2 and prostacyclin in cigarette smokers. Circulation 2005; 112: 1024-1029.
55. Vinals M, Martinez-Gonzalez J, Badimon L. Regulatory effects of HDL on smooth muscle cell prostacyclin release. Arterioscler Thromb Vasc Biol 1999; 19(10): 2405-2411.
56. Li SR, Yang Q, Koller E, Kurtaran A, Bischof C, Leimer M, Rauscha F, Pidlich J, Virgolini I. Modified LDL decreases the binding of prostaglandin E2, I2, and E1 onto monocytes in patients with peripheral vascular disease. Arterioscler Thromb Vasc Biol 1997; 17(10): 2066-2073.
57. Vinals M, Martinez-Gonzalez J, Badimon JJ, Badimon L. HDL-induced prostacyclin release in smooth muscle cells is dependent on cyclooxygenase-2 (Cox-2). Arterioscler Thromb Vasc Biol 1997; 17(12): 3481-3488.
58. 2α (a new and independent predictor of peripheral arterial disease). J Vasc Surg 2004; 40: 768-773.
59. Pillay PK, Pillay U, Balasubramaniam P, Lee KO. Platelet sensitivity to prostacyclin in diabetes mellitus. Ann Acad Med Singapore. 1985; 14(2): 229-231.
60. Betteridge DJ, El Tahir KE, Reckless JP, Williams KI. Platelets from diabetic subjects show diminished sensitivity to prostacyclin. Eur J Clin Invest 1982; 12(5): 395-398.
61. Zou MH, Shi C, Cohen RA. High glucose via peroxynitrite causes tyrosine nitration and inactivation of prostacyclin synthase that is associated with thromboxane/prostaglandin H(2) receptor-mediated apoptosis and adhesion molecule expression in cultured human aortic endothelial cells. Diabetes 2002; 51(1): 198-203.
62. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, D'Agostino RB, Kuller LH. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997; 145(5): 408-415.
63. Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42(2): 338-346.
64. Bruce, Ian N. BSR & BHPR Plenary Session: OP30. "Not Only...But Also": Factors that Contribute to Accelerated Atherosclerosis and Premature Coronary Heart Disease (CHD) in Systemic Lupus Erythematosus (SLE). Rheumatology 2005; 44 (Suppl1): i12-i13.
65. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349(25): 2399-2406.
66. Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 2002; 46(4): 862-873.
67. Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM, Ronda N, Jara LJ, Abu-Shakra M, Meroni PL, Sherer Y. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005; 112(21): 3337-3347.
68. Kabakov AE, Tertov VV, Saenko VA, Poverenny AM, Orekhov AN. The atherogenic effect of lupus sera: systemic lupus erythematosus-derived immune complexes stimulate the accumulation of cholesterol in cultured smooth muscle cells from human aorta. Clin Immunol Immunopathol 1992; 63: 214-220.
69. Reiss AB, Martin KO, Javitt NB, Martin DW, Grossi EA, Galloway AC. Sterol 27-hydroxylase: high levels of activity in vascular endothelium. J Lipid Res 1994; 35(6):1026-1030.
70. Janssen BA, Luqmani RA, Gordon C, Hemingway IH, Bacon PA, Gearing AJ, Emery P. Correlation of blood levels of soluble vascular cell adhesion molecule-1 with disease activity in systemic lupus erythematosus and vasculitis. Br J Rheumatol 1994; 33(12): 1112-6.
71. Ulbrich H, Soehnlein O, Xie X, Eriksson EE, Lindbom L, Albrecht W, Laufer S, Dannhardt G. Licofelone, a novel 5-LOX/COX-inhibitor, attenuates leukocyte rolling and adhesion on endothelium under flow. Biochem Pharmacol 2005; 70(1): 30-36.
72. Bishop-Bailey D, Burke-Gaffney A, Hellewell PG, Pepper JR, Mitchell JA. Cyclo-oxygenase-2 regulates inducible ICAM-1 and VCAM-1 expression in human vascular smooth muscle cells. Biochem Biophys Res Commun 1998; 249(1): 44-47.
73. Pratico D, Ferro D, Iuliano L, Rokach J, Conti F, Valesini G, FitzGerald GA, Violi F. Ongoing prothrombotic state in patients with antiphospholipid antibodies: a role for increased lipid peroxidation. Blood 1999; 193(10):3401-3407.
74. Suematsu N, Tsutsui H, Wen J, Kang D, Ikeuchi M, Ide T, Hayashidani S, Shiomi T, Kubota T, Hamasaki N, Takeshita A. Oxidative stress mediates tumor necrosis factor-alpha-induced mitochondrial DNA damage and dysfunction in cardiac myocytes. Circulation 2003; 107(10): 1418-1423.
75. Pruzanski W, Goulding NJ, Flower RJ, Gladman DD, Urowitz MB, Goodman PJ, Scott KF, Vadas P. Circulating group II phospholipase A2 activity and antilipocortin antibodies in systemic lupus erythematosus. Correlative study with disease activity. J Rheumatol 1994; 21(2): 252-257.
76. Wu R, Huang YH, Elinder LS, Frostegard J. Lysophosphatidylcholine is involved in the antigenicity of oxidized LDL. Arterioscler Thromb Vasc Biol 1998; 18(4): 626-630.
77. Manzi S, Wasko MC. Inflammation-mediated rheumatic diseases and atherosclerosis. Ann Rheum Dis 2000; 59(5): 321-325.
78. Prowse C, Pepper D, Dawes J. Prevention of the platelet alpha-granule release reaction by membrane-active drugs. Thromb Res 1982; 25(3): 219-227.
79. HOPE Study Investigators. Effects of an Ang-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342: 145-153.
80. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ. Second Australian National Blood Pressure Study: a comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348: 583-592.
81. Cipollone F, Fazia M, Iezzi A, Zucchelli M, Pini B, De Cesare D, Ucchino S, Spigonardo F, Bajocchi G, Bei R, Muraro R, Artese L, Piattelli A, Chiarelli F, Cuccurullo F, Mezzetti A. Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Circulation. 2003; 107(11): 1479-1485.
82. Cipollone F, Fazia M, Iezzi A, Pini B, Cuccurullo C, Zucchelli M, de Cesare D, Ucchino S, Spigonardo F, De Luca M, Muraro R, Bei R, Bucci M, Cuccurullo F, Mezzetti A. Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. Circulation 2004; 109(12): 1482-1488.
83. Li P, Ferrario CM, Brosnihan KB. Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats. J Cardiovas Pharmacol 1998;32(2):198-205.
84. Balsano F, Violi F and the ADEP Group. Effect of picotamide on the clinical progression of peripheral vascular disease; a doubleblind placebo-controlled study. Circulation 1993; 87: 1563-9.
85. Mehta J, Mehta P. Effects of propranolol therapy on platelet release and prostaglandin generation in patients with coronary heart disease. Circulation 1982; 66(6):1294-1299.
86. Ruf JC. Alcohol, wine and platelet function. Biol Res 2004;37(2):209-15.
87. Baysan O, Kaptan K, Erinc K, Oztas Y, Coskun T, Kayir H, Uzun M, Uzbay T, Beyan C, Isik E. Chronic heavy ethanol consumption is associated with decreased platelet aggregation in rats. Tohoku J Exp Med 2005; 206(2):85-90.
88. Delanty N, Reilly MP, Pratico D, Lawson JA, McCarthy JF, Wood AE, Ohnishi ST, Fitzgerald DJ, FitzGerald GA. 8-epi PGF2 alpha generation during coronary reperfusion. A potential quantitative marker of oxidant stress in vivo. Circulation 1997; 95(11): 2492-2499.
89. 2α and cytokines. Br J Pharmacol 2004;141: 488-496.
90. Jeremy JY, Shukla N, Muzaffar S, Angelini GD. Reactive oxygen species, vascular disease and cardiovascular surgery. Curr Vasc Pharmacol. 2004; 2: 229-236.
91. Muzaffar S, Shukla N, Angelini GD, Jeremy JY. Superoxide augments superoxide formation through NADPH oxidase expression in pulmonary arterial endothelial cells. Br J Pharmacol. 2004; in press.
92. Vane JR. The release and fate of vasoactive hormones in the circulation. Br J Pharmacol 1968; 35: 209-214.
93. Belch, JJ, Bell PR, Creissen D, Dormandy JA, Kester RC, McCollum RD, Mizushima Y, Ruckley, CV, Scurr JH, Wolfe JH. Randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug, in patients with intermittent claudication. Circulation 1997; 95(9): 2298-2302.
94. Anonymous. Prostanoids for chronic critical leg ischemia: a randomized, controlled, open-label trial with prostaglandin E1. Ann Intern Med 1999; 130(5): 412-421.
95. Emmerich J. Current state and perspective on medical treatment of critical leg ischemia: gene and cell therapy. Int J Low Extrem Wounds 2005; 4(4): 234-241.
96. Alt E, Haehnel I, Beilharz C, Prietzel K, Preter D, Stemberger A, Fliedner T, Erhardt W, Schomig A. Inhibition of neointima formation after experimental coronary artery stenting: a new biodegradable stent coating releasing hirudin and the prostacyclin analogue iloprost. Circulation 2000; 101(12): 1453-1458.
97. Lievre M, Morand S, Besse B, Fiessinger JN, Boissel JP. Oral Beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group. Circulation 2000; 102(4): 426-31.
98. Hayashi J, Ishida N, Sato H, Hata Y, Saito T. Effect of beraprost, a stable prostacyclin analogue, on red blood cell deformability impairment in the presence of hypercholesterolemia in rabbits. J Cardiovasc Pharmacol 1996; 27(4): 527-531.
99. Mohler ER 3rd, Hiatt WR, Olin JW, Wade M, Jeffs R, Hirsch AT. Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue: a double-blinded, randomized, controlled trial. J Am Coll Cardiol 2003; 41(10): 1679-86.
100. Archer SL, Gragasin FS, Webster L, Bochinski D, Michelakis ED. Aetiology and management of male erectile dysfunction and female sexual dysfunction in patients with cardiovascular disease. Drugs Aging 2005; 22(10): 823-844.
101. Urciuoli R, Cantisani TA, CarliniI M, Giuglietti M, Botti FM. Prostaglandin E1 for treatment of erectile dysfunction. Cochrane Database Syst Rev 2004; (2): CD001784.
102. Mansi MK, Alkhudair WK, Huraib S. Treatment of erectile dysfunction after kidney transplantation with intracavernosal self-injection of prostaglandin E1. J Urol 1998; 159(6): 1927-1930.
103. Wigley FM, Korn JH, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman M, Martin R, Collier DH, Weinstein A, Furst DE, Jimenez SA, Mayes MD, Merkel PA, Gruber B, Kaufman L, Varga J, Bell P, Kern J, Marrott P, White B, Simms RW, Phillips AC, Seibold JR. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum 1998; 41(4): 670-677.
104. nd, Lynch TG. Treatment of frostbite with intra-arterial prostaglandin E1. Am Surg 1983; 49(12): 665-667.
105. Sketch MH Jr, Whelton A, Schollmayer E, Koch JA, Bernink PJ, Woltering F, Brinker J, Prostaglandin E1 Study Group. Prevention of contrast media-induced renal dysfunction with prostaglandin E1: a randomized, double-blind, placebo-controlled study. Am J Ther 2001; 8(3):155-162.
106. Heyman SN, Rosen S, Brezis M. Radiocontrast nephropathy: a paradigm for the synergism between toxic and hypoxic insults in the kidney. Exp Nephrol 1994; 2: 153-157.
107. Thadani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med 1996; 334: 1448-1460.
108. Cantley LG, Spokes K, Clark B, McMahon EG, Carter J, Epstein FH. Role of endothelin and prostaglandins in radio-contrast-induced renal artery constriction. Kidney Int 1993; 44: 1217-1223.
109. 2 and prostacyclin inhibit the production and secretion of endothelin from cultured endothelial cells. J Biol Chem 1994; 269: 11938-11944.
110. Ruetten H, Ney P, Thiemermann C. E-type prostaglandins inhibit the synthesis of endothelin-1 by endothelial cells in culture. Prostagl Leukotr Essent Fatty Acids 1996; 55 (Suppl 1): 123.
111. Paller MS, Manivel JC. Prostaglandins protect kidneys against ischemic and toxic injury by a cellular effect. Kidney Int 1992; 42: 1345-1354.
112. Halcox JP. Deanfield JE. Childhood origins of endothelial dysfunction. Heart 2005; 91(10):1272-4.
113. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawin MA, Quyyumi AA, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348: 593-600.